Journal
NUTRIENTS
Volume 12, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/nu12082306
Keywords
quercetin; quercetin conjugates; cytochrome P450 enzymes; OATP transporters; ABC transporters; pharmacokinetic interaction; food drug interaction
Categories
Funding
- European Union
- European Social Fund [EFOP-3.6.1.-16-2016-00004]
- New National Excellence Program of the Ministry for Innovation and Technology [UNKP-19-3-IV-PTE-164]
- National Research, Development and Innovation Office (OTKA) [FK 128751]
- Biotechnology and Biological Sciences Research Council (BBSRC)
- Institute Strategic Programme Food Innovation and Health [BB/R012512/1, BBS/E/F/000PR10346, BBS/E/F/000PR10347]
- Biotechnology and Biological Sciences Research Council [BBS/E/F/000PR10346, BBS/E/F/00044434] Funding Source: researchfish
- BBSRC [BBS/E/F/000PR10346] Funding Source: UKRI
Ask authors/readers for more resources
Quercetin is a flavonoid, its glycosides and aglycone are found in significant amounts in several plants and dietary supplements. Because of the high presystemic biotransformation of quercetin, mainly its conjugates appear in circulation. As has been reported in previous studies, quercetin can interact with several proteins of pharmacokinetic importance. However, the interactions of its metabolites with biotransformation enzymes and drug transporters have barely been examined. In this study, the inhibitory effects of quercetin and its most relevant methyl, sulfate, and glucuronide metabolites were tested on cytochrome P450 (CYP) (2C19, 3A4, and 2D6) enzymes as well as on organic anion-transporting polypeptides (OATPs) (OATP1A2, OATP1B1, OATP1B3, and OATP2B1) and ATP (adenosine triphosphate) Binding Cassette (ABC) (BCRP and MRP2) transporters. Quercetin and its metabolites (quercetin-3 '-sulfate, quercetin-3-glucuronide, isorhamnetin, and isorhamnetin-3-glucuronide) showed weak inhibitory effects on CYP2C19 and 3A4, while they did not affect CYP2D6 activity. Some of the flavonoids caused weak inhibition of OATP1A2 and MRP2. However, most of the compounds tested proved to be strong inhibitors of OATP1B1, OATP1B3, OATP2B1, and BCRP. Our data demonstrate that not only quercetin but some of its conjugates, can also interact with CYP enzymes and drug transporters. Therefore, high intake of quercetin may interfere with the pharmacokinetics of drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available